Mangaluru: An expert committee constituted to examine the Kulai fishing harbour works has suggested the New Mangaluru Port Authority (NMPA) continue with the works and ensure that the quality and ...

This is the NMPA's latest retaliation against Spotify since the streaming service reclassified its premium subscriptions as 'bundles' in March, lowering royalties for publishers. By Kristin ...

The National Music Publishers’ Association (NMPA) has launched an ongoing takedown initiative against Spotify over the unlicensed use of music in podcasts on its platform. Notices will be sent ...

The NMPA constituted the committee with the approval of its board to examine the concerns about the project by the local fishermen. As suggested by the committee, Real Time Kinematic (RTK ...

Based on the results of the FLAMES study, the National Medicines Products Administration (NMPA) has approved the new drug application for Senaparib. The Wee1 inhibitor IMP7068 and the ATR ...

A separate NDA for the first-line treatment in adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 L858R mutations is currently under NMPA review.

Acceptance of the drug application by the NMPA marks an essential step in introducing NVK002 as a potential therapeutic option for managing myopia in children across China. “NMPA acceptance of ...

Credit: Pormezz/Shutterstock. China’s National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application (NDA) for Stapokibart to treat seasonal ...

This morning, The National Music Publishers’ Association (NMPA) announced that it had launched a takedown initiative against Spotify over the alleged unlicensed use of music in podcasts on its ...

This is not the first time the NMPA has gone after Spotify. The group sued the company in June of 2024 for its music-audiobook bundling deal, claiming it cut royalties for songwriters. Spotify ...

“This regulatory clearance from the NMPA marks an important milestone in advancing our efforts to address significant unmet needs in immunological diseases,” said Dr. Jingsong Wang, Founder, Chairman, ...

Currently valued at approximately KRW 500 billion, the company is poised for a new leap forward with the NMPA approval. CEO Hwan-Chul Lee stated, “Stock prices reflect a company’s growth and stability ...